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1. INTRODUCTION {#ejh13218-sec-0001}
===============

Secondary acute myeloid leukemia (sAML) evolving from an antecedent hematological disorder and therapy‐related sAML represent high‐risk subsets of AML and are associated with poor clinical outcome.[1](#ejh13218-bib-0001){ref-type="ref"} The hypomethylating agents (HMA), azacitidine, and decitabine represent treatment options for elderly AML patients including sAML patients unfit for intensive chemotherapy.[2](#ejh13218-bib-0002){ref-type="ref"}, [3](#ejh13218-bib-0003){ref-type="ref"}, [4](#ejh13218-bib-0004){ref-type="ref"}, [5](#ejh13218-bib-0005){ref-type="ref"} Treatment options after HMA failure usually consist of BSC or low‐dose cytarabine, and the prognosis remains limited with a median OS of 3.4 months.[6](#ejh13218-bib-0006){ref-type="ref"} Therefore, there is a high clinical demand for new therapeutic targets. BCL‐2 mediates malignant cell survival by interfering with pro‐apoptotic factors such as BAX, thereby preventing mitochondrial outer membrane permeabilization (MOMP) and finally preventing apoptosis.[7](#ejh13218-bib-0007){ref-type="ref"} Higher BCL‐2 expression has prognostic impact and is associated with lower response rates to intensive chemotherapy and shorter survival in AML.[8](#ejh13218-bib-0008){ref-type="ref"}, [9](#ejh13218-bib-0009){ref-type="ref"} The selective oral BCL‐2 inhibitor ABT‐199 (venetoclax) has demonstrated promising responses in advanced‐stage MDS, sAML,[10](#ejh13218-bib-0010){ref-type="ref"} and high‐risk relapsed/refractory AML (including 54% with sAML) as monotherapy[11](#ejh13218-bib-0011){ref-type="ref"} as well as in combination with low‐dose cytarabine[12](#ejh13218-bib-0012){ref-type="ref"} or with HMA[13](#ejh13218-bib-0013){ref-type="ref"}, [14](#ejh13218-bib-0014){ref-type="ref"} in elderly untreated AML patients unfit for intensive chemotherapy.

In this case series, we report the clinical outcome and biomarker correlates of seven elderly sAML patients receiving venetoclax after treatment failure with HMA.

2. PATIENTS AND METHODS {#ejh13218-sec-0002}
=======================

Included patients were diagnosed with relapsed/refractory AML defined by the World Health Organization classification[15](#ejh13218-bib-0015){ref-type="ref"} and considered unfit for intensive induction chemotherapy. Venetoclax monotherapy was administered within a named patient program after failure of conventional therapies including HMA with a ramp‐up dosing schedule and a target dose of 800 mg per day as previously reported.[11](#ejh13218-bib-0011){ref-type="ref"} All patients signed an informed consent for the off‐label use of venetoclax, and all patients alive at the time point of data acquisition signed an informed consent to allow collection of personal data. Therapy response was evaluated by the revised International Working Group (IWG) criteria.[16](#ejh13218-bib-0016){ref-type="ref"} Primers for isocitrate dehydrogenase (IDH) 1 and 2 exon 4 analysis and PCR conditions were used as previously described.[17](#ejh13218-bib-0017){ref-type="ref"} Immunohistochemical staining was performed in myeloblasts based on pretreatment bone marrow aspirates/biopsies, which had been obtained during routine clinical care, using a Bond RXm system (Leica, Wetzlar) with primary antibodies against BCL‐2 (M0887, DAKO, Agilent, Santa Clara, CA), BIM (ADI‐AAP‐330, Enzo Life Sciences, Farmingdale, NY), and MCL‐1 (16225‐1‐AP, Rosemont, IL). Briefly, slides were deparaffinized using deparaffinization solution, pretreated with epitope retrieval solution 1 (corresponding to citrate buffer pH6) for 50 or 30 minutes, for MCL‐1 and BCL‐2, respectively, or epitope retrieval solution 2 (corresponding to EDTA buffer pH8) for 30 minutes for BIM. Antibody binding was detected with a polymer refine detection kit without postprimary reagent and visualized with DAB as a dark brown precipitate. Counterstaining was done with hematoxylin. As a positive control, healthy human tonsil tissue was used.

3. RESULTS AND DISCUSSION {#ejh13218-sec-0003}
=========================

Between April 2017 and September 2018, seven patients with relapsed/refractory AML received venetoclax after treatment failure with HMA at our tertiary cancer center in Salzburg, Austria. At data cut‐off (10/19/2018), all seven patients had discontinued venetoclax treatment due to progression and six patients had died. The patient baseline characteristics are shown in Table [1](#ejh13218-tbl-0001){ref-type="table"}.

###### 

Patient characteristics and biomarker correlates of seven secondary AML patients treated with venetoclax

  Patient   Age at AML diagnosis   Sex      Antecedent hematologic malignancy            Time to leukemic transformation (days)   Best response to HMA (IWG)   Cytogenetics   IDH1/2 mutation status   BCL‐2 expression by IHC   MCL‐1 expression by IHC   BIM expression by IHC   WBC at venetoclax start (G/L)   Best response to venetoclax (IWG)           Peripheral blast clearing during venetoclax   Survival status   PFS on prior therapy (days)   Non‐hematologic venetoclax toxicity      Venetoclax dose modification                      PFS on venetoclax (days)   OS from venetoclax initiation (days)
  --------- ---------------------- -------- -------------------------------------------- ---------------------------------------- ---------------------------- -------------- ------------------------ ------------------------- ------------------------- ----------------------- ------------------------------- ------------------------------------------- --------------------------------------------- ----------------- ----------------------------- ---------------------------------------- ------------------------------------------------- -------------------------- --------------------------------------
  \#24231   74                     Female   MDS                                          483                                      TF                           46 XX          IDH1 mutant              4                         0                         0                       11.0                            NA[b](#ejh13218-note-0004){ref-type="fn"}   Day 9                                         Dead              222 (decitabine)              Diarrhea (III°)                          Intermittent 200 mg dose (thrombocytopenia IV°)   70                         126
  \#8623    75                     Female   MDS                                          1429                                     TF                           46 XX          Wild‐type                4                         0.5                       0.5                     0.7                             CR                                          Day 21                                        Alive             110 (azacitidine)             None                                     None                                              505                        549
  \#6510    74                     Male     MDS/MPN (CMML)                               299                                      TF                           46 XY          Wild‐type                1                         0                         0                       9.0                             TF                                          ‐                                             Dead              240 (azacitidine)             Fever (II°)                              Temporary interruption                            6                          36
  \#25984   81                     Female   MDS[a](#ejh13218-note-0003){ref-type="fn"}   NA                                       PR                           46 XX          Wild‐type                1                         0                         1.0                     76.0                            TF                                          ‐                                             Dead              325 (azacitidine)             None                                     None                                              6                          15
  \#23769   65                     Male     MDS[a](#ejh13218-note-0003){ref-type="fn"}   NA                                       CRi                          46 XY          Wild‐type                1                         0.5                       1.0                     2.0                             TF                                          ‐                                             Dead              258 (azacitidine)             Unconjugated hyperbilirubinemia (II°)    None                                              18                         24
  \#14501   73                     Male     ET                                           1885                                     NA                           46 XY          Wild‐type                1                         0                         0.5                     269.0                           TF                                          ‐                                             Dead              12 (azacitidine)              None                                     None                                              33                         55
  \#17397   82                     Male     PV                                           942                                      TF                           NA             IDH2 mutant              1                         1.0                       1.5                     170.0                           CR                                          Day 21                                        Dead              37 (azacitidine)              Unconjugated hyperbilirubinemia (III°)   Intermittent 200 mg dose                          352                        364

BM, bone marrow; CMML, chronic myelomonocytic leukemia; CR, complete remission; CRi, complete remission with incomplete hematologic recovery; ET, essential thrombocythemia; HMA, hypomethylating agents; IDH, isocitrate dehydrogenase; IWG, International Working Group; MDS, myelodysplastic syndrome; MPN, myeloproliferative neoplasm; NA, not available; OS, overall survival; PFS, progression‐free survival; PR, partial remission; PV, polycythemia vera; sAML, secondary acute myeloid leukemia; TF, treatment failure; WBC, white blood count.

Classified as sAML based on bone marrow aspirate/biopsy and/or peripheral blood smear.

Response not evaluable by IWG criteria as no bone marrow re‐evaluation was performed.
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The median age at initial diagnosis of AML was 74 years and ranged between 65 and 82 years. All seven patients were diagnosed with secondary AML: four patients had an antecedent myelodysplastic syndrome (MDS), two patients developed leukemic transformation based on chronic myeloproliferative neoplasms, and one patient suffered from antecedent chronic myelomonocytic leukemia. All patients were refractory to HMA at the start of venetoclax treatment with a median PFS of 222 days (range 12‐325 days) on prior hypomethylating therapy. Median OS from venetoclax initiation was 55 days (range: 15‐549 days, Figure [1](#ejh13218-fig-0001){ref-type="fig"}A). One patient with antecedent MDS and one with antecedent myeloproliferative neoplasm achieved a complete remission with a PFS of 505 and 352 days, respectively. Despite the limited number of patients included in this retrospective analysis, exceptionally long response durations were observed with venetoclax monotherapy in pretreated sAML in comparison to previous studies.[11](#ejh13218-bib-0011){ref-type="ref"} A third patient derived antileukemic benefit from venetoclax and showed complete peripheral blood blast clearing by day 9 but did not meet response criteria defined by the IWG as no bone marrow evaluation was performed. Rapid disease progression (≤35 days upon venetoclax start) was documented in the four non‐responders. High BCL‐2 and/or BIM expression (Figure [1](#ejh13218-fig-0001){ref-type="fig"}B) identified venetoclax responders, and response was associated with superior median OS (responders: 364 days vs non‐responders: 24 days, *P* = 0.018, Figure [1](#ejh13218-fig-0001){ref-type="fig"}C). High expression of BCL‐2 may be a sign of so‐called BCL‐2 addiction, a concept describing a situation where cells expressing high levels of BH3‐only proteins can only survive by overexpression of BCL‐2. Such cells may be close to a threshold that can be effectively overcome by venetoclax.[18](#ejh13218-bib-0018){ref-type="ref"} On the other hand, a high expression of a pan‐BCL‐2‐inhibitory BH3‐only protein such as BIM may also indicate a therapeutic window of venetoclax, since its displacement may overcome MCL‐1 dependent protection. Two of three venetoclax responders harbored IDH1 or IDH2 mutations, which are known to lower the mitochondrial threshold for initiation of apoptosis upon venetoclax therapy[19](#ejh13218-bib-0019){ref-type="ref"} and thereby increase response rates.[11](#ejh13218-bib-0011){ref-type="ref"} This may be associated with alterations in the BCL‐2 family, but we were not able to discern a uniform pattern of BCL‐2 family alterations. Interestingly, median OS from venetoclax initiation was significantly longer in patients with primary HMA refractory disease compared to HMA‐responders (126 days vs 15 days; *P* = 0.018). In previous AML studies, patients with a WBC exceeding 25 G/L were excluded from venetoclax treatment.[11](#ejh13218-bib-0011){ref-type="ref"}, [14](#ejh13218-bib-0014){ref-type="ref"}, [20](#ejh13218-bib-0020){ref-type="ref"} Despite a baseline WBC of up to 269 G/L (range 0.7‐269 G/L) at venetoclax initiation, we did not observe tumor lysis syndrome.

![Overall Survival of Seven Secondary AML Patients Refractory to Hypomethylating Agents from Venetoclax Initiation (A), Immunohistochemistry for BCL‐2, BIM, and MCL‐1 on Myeloblasts (B), and Overall Survival From Venetoclax Initiation Based on Venetoclax Therapy Response (C). A, The tick marks on the curves represent censored patients. B, BCL‐2, BIM, and MCL‐1 expression on myeloblasts based on pretreatment bone marrow biopsies/aspirates. C, Responders included patient \#8623 (CR), \#17397 (CR), and \#24231 (rapid peripheral blast clearing). The tick marks on the curves represent censored patients](EJH-102-437-g001){#ejh13218-fig-0001}

In summary, venetoclax monotherapy proved effective in elderly sAML patients after treatment failure with HMA, including a patient with antecedent myeloproliferative neoplasm. Responses were clinically apparent within 4‐6 weeks, favoring a short trial of venetoclax in patients without standard options. High baseline BCL‐2 and/or BIM expression may identify responders to venetoclax treatment. These findings should be validated in future clinical trials.
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